Key result
Lipoprotein(a) confers a continuous residual cardiovascular risk during statin therapy, despite the use of clinical thresholds to guide treatment decisions.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Discusses the continuous nature of residual risk associated with Lipoprotein(a) levels during statin therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ammar et al. (2026) studied this question. Lipoprotein(a) confers a continuous residual cardiovascular risk during statin therapy, despite the use of clinical thresholds to guide treatment decisions.
Synapse has enriched 10 related papers. Consider them for comparative context: